Company: BDRX
Filing Date: 2025-11-03
Form Type: 424B3
Source: 0001214659-25-015745
Chunk: 4

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-03
Form: 424B3
Chunk 4
---
,600 in Europe. Importantly, mTOR has been shown to
be over-expressed in FAP polyps – thereby underscoring the rationale for using an mTOR inhibitor like eRapa to treat FAP.

About eRapa

eRapa is a proprietary
oral capsule formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (ammalian arget f apamycin)
inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation
and is activated during tumorgenesis. Rapamycin is approved in the US for organ rejection in renal transplantation as Rapamune®.
Through the use of nanotechnology and pH sensitive polymers, eRapa is designed to address the poor bioavailability, variable pharmacokinetics
and toxicity generally associated with the currently available forms of rapamycin. eRapa is protected by a number of issued patents which
extend through 2035, with other pending applications potentially providing further protection beyond 2035.

1. www.rarediseases.org

2. www.orpha.net

3. Tian
et al., mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy, Int
J Mol Sci. 2019 Feb; 20(3): 755

For more information, please contact:

| Biodexa Pharmaceuticals PLC |
| Stephen Stamp, CEO, CFO     
 Gary Shangold, CMO          |
| Tel: +44 (0)29 20480 180    |
| www.biodexapharma.com       |

About Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC (listed on NASDAQ:
BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet
medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle
Invasive Bladder Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive
rare/orphan brain cancer indications.

eRapa is a proprietary oral capsule formulation
of rapamycin, also known as sirolimus. Rapamycin is an mTOR (ammalian arget f apamycin) inhibitor. mTOR
has been shown to have a